CSE:LOBE

Lobe Sciences to Present at Virtual One2One Investor Forum

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") announces that Philip Young, CEO and Director, will be interviewed on Tuesday, February 23rd, 2021 at 1:00 pm EST by broadcast journalist Christine Corrado of Proactive Investors, a leading multi-media news organization, investor portal and events management business with offices in New York, Sydney, Toronto, Frankfurt, and London.

The Virtual One2One Investor Forum invitation will be sent to Proactive's 20,000 YouTube subscribers and will be broadcasted internationally. The audience will consist of high-net-worth investors, fund managers, private client brokers and analysts. Lobe's presentation will be followed by a Q&A session and it will be published online.

Recent Company highlights & topics to be discussed include:

  • The successful completion and testing of the proof-of-concept prototype of its proprietary nasal mist device
  • Pre-clinical study of psilocybin plus NAC for treatment of PTSD and mTBI with the University of Miami
  • The appointment of Philip Young as CEO and Director
  • The closing of an upsized $3,445,847 non-brokered private placement
  • The appointment of Jonathan Gilbert as Executive Chairman
  • Executed LOI for CAD$23 million sale of certain assets related to Cowlitz County Cannabis Cultivation Inc.

About Lobe Sciences Ltd.

Lobe Sciences is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.

For further information please contact:

Lobe Sciences Ltd.
Philip J Young, CEO
info@lobesciences.com
Tel: (949) 505-5623

THE CSE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

Disclaimer for Forward Looking Statements

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact included in this release, including statements regarding the future plans and objectives of the Company, progression with nasal mist device engineering and commercialization, the pursuit of M&A initiatives, development of effective delivery methods and commercialization potential of the nasal mist device, research and development using NAC and psilocybin and growth of the business, are forward looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations are risks detailed from time to time in the filings made by the Company with securities regulations. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including changes to the regulatory environment; and that the current Board and management may not be able to attain the Company's corporate goals and objectives. As a result, the Company cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made only as of the date of this news release and the Company does not intend to update any of the included forward-looking statements except as expressly required by applicable Canadian securities laws.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/74972

News Provided by Newsfile via QuoteMedia

The Conversation (0)
Cannabis leaves, US flag.

Cannabis Round-Up: DEA Postpones Rescheduling Hearing, Key Players Share Quarterly Results

November was a busy month for the cannabis industry, with a slew of US-centric developments.

A hearing on cannabis rescheduling was postponed until 2025, although the incoming Trump administration has signaled its intent to follow through on the change despite opposition from some Republican lawmakers.

Meanwhile, several states voted on cannabis measures, and companies reported their latest quarterly results.

Keep reading...Show less
Cannabis plants and a stock chart.

US Cannabis Sales Hit Record in October, Market Set to Reach US$55 Billion by 2030

Cannabis sales in the US reached a record high in October, with retail transactions totaling approximately US$2.8 billion, according to data from LeafLink, a wholesale cannabis platform.

While sales saw a slight 2.1 percent dip compared to September, they were up 6.2 percent year-on-year. Total retail cannabis sales in 2024 are expected to hit US$32.6 billion, representing a 10.8 percent increase over the previous year.

LeafLink attributes much of this growth to new licenses in states such as New York, New Jersey and Ohio.

Keep reading...Show less
Australia flag and cannabis.

Australian Senate Rejects Greens' Bill to Legalise Cannabis

The Australian Greens announced on Wednesday, November 27, that the Legalising Cannabis Bill 2023 was defeated in a 13 to 24 vote, preventing the federal legalisation of cannabis.

“The Labor and Coalition parties joined together to try and hold Australia back in the 1950s by blocking this desperately needed reform,” said Greens Senator for New South Wales David Shoebridge.

Shoebridge said on X that the parties “teamed up” to vote against legalizing cannabis in the Senate, “yet another example of the major parties working together to refuse any sort of progress.”

All 11 Greens Senators voted in favour of the Bill, as did Independent Senators Lidia Thorpe and Tammy Tyrrell.

Keep reading...Show less
Cannabis and Australian money.

Victoria Amends Driving Rules for Medicinal Cannabis Users, Changes Effective in Mid-2025

Both houses of parliament in Victoria, Australia, have successfully passed the Roads and Road Safety Legislation Amendment Bill 2024, Cannabis Council Australia said in a recent newsletter.

The organisation sees this as a “promising development” in the area, calling it a “critical legislative milestone." The bill's passing will allow for judicial discretion when decisions about medicinal cannabis are made.

Magistrates will now have the ability to evaluate individual cases where drivers who hold valid medicinal cannabis prescriptions test positive for THC, but show no signs of impairment.

Keep reading...Show less

Trulieve to Open Medical Cannabis Dispensary in Jacksonville, Florida

New Duval County location will host grand opening celebration Friday, December 6 th

Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., announced the opening of a new medical cannabis dispensary in Jacksonville, Florida on Saturday, November 23 .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Trulieve Cannabis Corp. Announces Insider Share Purchases By Executive Leadership and Board Members

Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced that several members of its executive management team and board of directors have recently made purchases of the company's subordinate voting shares, signaling their confidence in the company's growth potential and direction.

Trulieve logo (PRNewsfoto/Trulieve Cannabis Corp.)

Between November 8, 2024 and November 21, 2024 , Chairman and CEO Kim Rivers , Director Thad Beshears , Director Peter Healy , Director Richard May , Director Thomas Milner , Director Jane Morreau , Director Susan Thronson , Chief Marketing Officer Gina Collins , Chief Technology Officer Nilyum Jhala, Chief Production Officer Kyle Landrum , Chief Information Officer Jason Pernell , Chief Legal Officer Eric Powers , Chief Operating Officer Marie Zhang , and Vice President of Investor Relations Christine Hersey purchased a total of 72,273 shares at prices between $5.63 and $7.19 per share. These insider purchases reflect the confidence and commitment of leadership in the long-term strategic plan for Trulieve and its shareholders.

About Trulieve
Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S., with leading market positions in Arizona, Florida, and Pennsylvania. Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to cannabis, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF. For more information, please visit Trulieve.com .

Facebook: @Trulieve
Instagram: @Trulieve _
X: @Trulieve

Investor Contact  
Christine Hersey , Vice President of Investor Relations
+1 (424) 202-0210
Christine.Hersey@Trulieve.com

Media Contact  
Phil Buck , APR, Corporate Communications Manager
+1 (406) 370-6226
Philip.Buck@Trulieve.com

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/trulieve-cannabis-corp-announces-insider-share-purchases-by-executive-leadership-and-board-members-302313784.html

SOURCE Trulieve Cannabis Corp.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/November2024/22/c2393.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×